Metraipolis › archive › dc_6a538e8094eb

Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies — Europe PMC PMID:41069341

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41069341
DOI
10.3389/fonc.2025.1645438
License (as archived)
solo-consultazione
Archived
2026-11-09T20:16:45.415Z
SHA-256 of the archived text
a04f6a538ee2750c172ddb077e9f9f984cb02693b0038d27b1f94b7dc12dc7ab
Stable URL of this page
https://metraipolis.com/documento/dc_6a538e8094eb

How to cite

Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies — Europe PMC PMID:41069341 — Europe PMC (en), https://europepmc.org/article/MED/41069341 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6a538e8094eb (Metraipolis archive dc_6a538e8094eb, sha256 a04f6a538ee2750c172ddb077e9f9f984cb02693b0038d27b1f94b7dc12dc7ab)
BibTeX
@misc{dc6a538e8094eb,
  title = {Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies — Europe PMC PMID:41069341},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41069341},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6a538e8094eb; sha256 a04f6a538ee2750c172ddb077e9f9f984cb02693b0038d27b1f94b7dc12dc7ab},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41069341. Agents can read the archived copy with the MCP tool read_document.